Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study

Naunyn Schmiedebergs Arch Pharmacol. 1991 Sep;344(3):263-74. doi: 10.1007/BF00182999.

Abstract

The partial dopamine receptor agonists SDZ 208-911 (N-[(8-alpha)-2,6-dimethylergoline-8-yl]-2,2-dimethylpropanamid e), SDZ 208-912 (N-[8-alpha)-2-chloro-6-methylergoline-8-yl]-2,2- dimethylpropanamide) and terguride (transdihydrolisuride; TDHL) were tested in biochemical, behavioral (locomotor activity) and electrophysiological assays in male rats. In reserpine-pretreated rats, SDZ 208-911 and terguride dose-dependently reduced striatal DOPA formation (NSD 1015 treatment) with similar efficacy (-80%) and potency as the selective D2 receptor agonist quinpirole (LY 171555). SDZ 208-912 only produced a partial reduction (-32%) at the highest dose tested. SDZ 208-911 and terguride partially reversed (by approximately 50%) the gamma-butyrolactone (GBL)-induced increase in striatal DOPA accumulation. Quinpirole produced a 100% reversal while SDZ208-912, per se, was inactive. While quinpirole decreased DOPA accumulation, all three partial agonists elevated striatal DOPA accumulation in non-pretreated rats with SDZ 208-912 being as potent and efficacious as haloperidol. The three partial agonists displayed comparatively high affinities in vitro for the dopamine D2 (3H-spiperone) receptor site and somewhat lower affinity for the 5-HT1A (3H-8-OH-DPAT) receptor site. SDZ 208-911 and SDZ 208-912 also showed high affinities for central alpha 2 (3H-idazoxane) receptors. In line with these findings, the partial ergoline agonists dose-dependently elevated the DOPA accumulation in the noradrenaline-rich cortical brain region and decreased the 5-HT synthesis rate (5-HTP accumulation) in the limbic brain region. Furthermore, high doses of SDZ 208-911 and terguride produced weak signs of the 5-HT behavioral syndrome (flat body posture) in reserpinized rats. In the locomotor activity studies in non-pretreated rats, SDZ 208-911, SDZ 208-912 and terguride reduced the activity to 10-20% of controls with SDZ 208-912 being approximately ten times less potent than the other two compounds. Weak postsynaptic dopamine receptor agonist effects of the partial agonists were demonstrated only in reserpine-pretreated rats; all three partial agonists tested produced occasional forward locomotion and the so-called "jerking" behavior. Extracellular single unit recordings were carried out in chloral hydrate-anesthetized rats to investigate the effects on firing rates of dopamine neurons located in the substantia nigra pars compacta. Intravenous administration of SDZ 208-911 and terguride depressed the firing rate by 42 and 53%, respectively, while apomorphine completely inhibited the cells. SDZ 208-912 only reduced the firing by 16% and some cells displayed a biphasic response with a weak depression at low doses that disappeared at high doses.(ABSTRACT TRUNCATED AT 400 WORDS)

Publication types

  • Comparative Study

MeSH terms

  • 4-Butyrolactone / pharmacology
  • Animals
  • Behavior, Animal / drug effects
  • Brain / drug effects
  • Brain / metabolism
  • Dopamine / biosynthesis
  • Dopamine Agents / pharmacology*
  • Ergolines / pharmacology*
  • Lisuride / analogs & derivatives*
  • Lisuride / pharmacology
  • Male
  • Motor Activity / drug effects
  • Neurons / drug effects
  • Neurons / physiology
  • Quinpirole
  • Rats
  • Rats, Inbred Strains
  • Receptors, Dopamine / physiology*
  • Receptors, Serotonin / metabolism
  • Reserpine / pharmacology
  • Serotonin / biosynthesis
  • Substantia Nigra / cytology
  • Substantia Nigra / drug effects
  • Substantia Nigra / physiology
  • Time Factors

Substances

  • Dopamine Agents
  • Ergolines
  • Receptors, Dopamine
  • Receptors, Serotonin
  • N-(2,6-dimethylergoline-8-yl)-2,2-dimethylpropanamide
  • N-(2-chloro-6-methylergoline-8-yl)-2,2-dimethylpropanamide
  • Quinpirole
  • dironyl
  • Serotonin
  • Reserpine
  • Lisuride
  • 4-Butyrolactone
  • Dopamine